Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | NPY4R | P50391 | 6/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | NPY1R | P25929 | 4/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909028 | 1.00 | PTGS1 (0.45) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL18932741 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL17722910 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL21474404 | 0.89 | PTGS1 (0.45) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL19681467 | 0.89 | PTGS1 (0.45) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL22694944 | 0.89 | PTGS1 (0.46) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL20864073 | 0.89 | PTGS1 (0.44) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL22668929 | 0.89 | PTGS1 (0.44) | PTGS1PTGS2ITGB3ITGA2BPTPN1 | |
| SCHEMBL25094826 | 0.86 | FAP (0.37) | PTGS1PTGS2NPY4RNPY5RNPY1R | |
| SCHEMBL26058204 | 0.86 | FAP (0.37) | PTGS1PTGS2NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | PTGS1 4828/4885PTGS2 4820/4885ITGB3 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.